Current Highlight from October 5, 2012
Biomarker Discovery and Qualification
An NCTR scientist presented a keynote address at the IMPROVER Symposium that was held in Boston, Mass. on October 2-3, 2012. The presentation focused on biomarker discovery and qualification and specifically addressed the need for new biomarkers, the multiple omics approaches used at NCTR, and the use of pharmacogenomics biomarkers in preclinical and clinical applications. The goal of the symposium was to discuss the results and approaches from the IMPROVER challenge, which was a competition to find diagnostic signatures from mRNA data in four areas: chronic obstructive pulmonary disease each, lung cancer, psoriasis, and multiple sclerosis.
For additional information, please contact Donna Mendrick, Ph.D., Director, Division of Systems Biology, FDA/NCTR.
Nanotechnology for Health Care Conference
Scientists from NCTR presented their research results at the 4th Annual Nanotechnology for Health Care Conference held at the Winthrop Rockefeller Institute near Morrilton, Ark, on September 26-29, 2012 she. The topics of the presentations included approaches to evaluate the toxicity of nanomaterials and summaries of nanotoxicology projects in Arkansas research institutions.
For additional information, please contact Paul Howard, Ph.D., Director, Office of Scientific Coordination, FDA/NCTR.
Leflunomide-Induced Liver Injury
An NCTR scientist gave a presentation at the Developing More Predictive In Vitro Models 3rd Annual Summit that was held in Boston, Mass., on September 26-27, 2012. The presentation focused on studies that indicate involvement of toxic reactive metabolites, CYP polymorphisms, and CYP-inhibitory drugs in leflunomide-induced liver injury. The goal of the meeting was to provide a forum for experts from industry, academia, and government to discuss cutting-edge advancements and to debate challenges and solutions to develop more predictive in vitro models.
For additional information, please contact Xi Yang, Ph.D., Innovative Safety and Technologies Branch, Division of Systems Biology, FDA/NCTR.
Biomarkers of Acetaminophen-Induced Toxicity
An NCTR scientist gave a presentation at Metabomeeting 2012 held in Manchester, United Kingdom, on September 25-27, 2012. The talk presented research data concerning clinical serum metabolic biomarkers of pediatric acetaminophen overdose. The goal of the meeting was for further development of metabolic profiling and its applications that include metabolic research in plants, microbes, preclinical screening, nutrition, and human health.
For additional information, please contact Richard Beger, Ph.D., Director, Biomarkers and Alternative Models Branch, Division of Systems Biology, FDA/NCTR.
Organization of Economic Cooperation and Development (OECD) Test Guidelines
Two NCTR scientists participated in the OECD Expert Work Group for Genotoxicity Test Guidelines held in Paris, France, on September 24-28, 2012. As members of the OECD expert workgroup, the NCTR scientists are providing leadership in various subgroups as the OECD is drafting new guidelines and revising a number of the current OECD Test Guidelines for genotoxicity testing. Genetic toxicology tests are used as a part of the hazard identification evaluation for a number of different FDA-regulated product classes.
For additional information, please contact Robert Heflich, Ph.D., Division of Genetic and Molecular Toxicology, FDA/NCTR, or Martha Moore, Ph.D., Director, Division of Genetic and Molecular Toxicology, FDA/NCTR.